Plasmid DNA is a small, self-replicating DNA molecule that exists separate from the chromosomal DNA of an organism. Plasmid DNA manufacturing is an advanced biotechnological process used to produce plasmid DNAs in large quantities for various applications including gene therapy, DNA vaccination, molecular cloning, diagnostic, and research. Growing preference for plasmid DNA as a therapeutic agent and rising demand for gene and cell therapies have propelled the need for plasmid DNA manufacturing across the globe.
The Global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 1038.19 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.
Growing demand for plasmid DNA from the pharmaceutical and biotechnology industries for applications such as DNA vaccines, gene therapy, and molecular biology research is driving the Global Plasmid DNA Manufacturing Market Demand Additionally, development and commercialization of novel drugs and therapies have augmented the requirement for advanced manufacturing capabilities and high-quality plasmid DNA, thereby fueling market growth.
Expanding applications of plasmid DNA in cell and gene therapies combined with increasing R&D investments by major players to develop large-scale manufacturing capabilities is fueling the global expansion of the plasmid DNA manufacturing market. Moreover, rising biopharmaceutical industry and growing focus on precision medicine are creating numerous opportunities for plasmid DNA manufacturers across the globe.
Market key Trends
One of the key trends witnessed in the Plasmid DNA Manufacturing Market is the surge in outsourcing activities. Large pharmaceutical companies are outsourcing plasmid DNA manufacturing processes to contract development and manufacturing organizations (CDMOs) in order to focus on drug development. This is allowing end-users to reduce capital expenditure and access advanced technologies through outsourcing. As a result, CDMOs with large-scale plasmid DNA manufacturing capabilities are gaining increased popularity worldwide.
Porter’s Analysis
Threat of new entrants: Low capital requirements for Plasmid DNA manufacturing limits threat of new entrants. However, established players have economies of scale and scope.
Bargaining power of buyers: Individual buyers have little bargaining power due to specialized nature of Plasmid DNA. However, large pharma companies can negotiate on volume and price.
Bargaining power of suppliers: Key raw materials like media, buffers etc are standardized and widely available. However, suppliers of specialty cell lines and master cell banks have some pricing power.
Threat of new substitutes: No close substitutes exist for Plasmid DNA in gene and cell therapy. However, synthetic gene and RNA based approaches could emerge as alternatives.
Competitive rivalry: Presence of many mid-sized players results in intense competition. Players compete based on quality, reliability, pricing and single use technologies.
Geographical Regions
North America currently accounts for the largest share of the global Plasmid DNA manufacturing market, driven by presence of leaders in gene therapy clinical research and commercialization. The US and Canada are hubs of gene therapy clinical trials and commercial approvals.
The Asia Pacific region is expected to be the fastest growing market for Plasmid DNA manufacturing. Countries like China, India, Japan and South Korea are aggressively investing in genome editing and cell and gene therapy infrastructure. Favorable regulatory environment and lower production costs are attracting investors to the region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.